The Drugs Controller General of India (DCGI) on January 3 granted restricted emergency use authorisation for the Serum Institute of India (SII)’s ‘Covishield’ and Bharat Biotech’s ‘Covaxin’ vaccines against COVID-19, the disease caused by the novel coronavirus.
The ‘Covishield’ vaccine, developed by University of Oxford and pharmaceutical giant AstraZeneca, is being produced in the country by the Serum Institute. Bharat Biotech has developed ‘Covaxin’ – India’s first indigenous vaccine against COVID-19.
In a series of tweets, Prime Minister Narendra Modi congratulated Serum Institute and Bharat Biotech for getting the requisite approvals and said the decision will "accelerate the road to a healthier and COVID-free nation". "Congratulations to our hardworking scientists and innovators," PM Modi said.